Denosumab versus zoledronic acid in patients previously treated with zoledronic acid

Anastasilakis A. D.; Polyzos S. A.; Gkiomisi A.; Saridakis Z. G.; Digkas D.; Bisbinas I.; Sakellariou G. T.; Papatheodorou A.; Kokkoris P.; Makras P.

首页> 外文期刊>Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA >Denosumab versus zoledronic acid in patients previously treated with zoledronic acid

【24h】

Denosumab versus zoledronic acid in patients previously treated with zoledronic acid

机译：曾接受唑来膦酸治疗的患者中地诺单抗与唑来膦酸的关系

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The Summary Denosumab and zoledronic acid are potent antiresorptives. In this study in patients pre-treated with zoledronic acid, denosumab achieved similar increases with zoledronic acid in lumbar spine BMD despite the more prominent reduction of bone turnover markers. Denosumab reversibly reduced endogenous RANKL.

机译：总结地诺单抗和唑来膦酸是有效的抗吸收剂。在这项研究中，唑来膦酸预处理的患者中，狄诺塞麦在腰椎BMD中与唑来膦酸达到了相似的增加，尽管骨转换指标明显降低。地诺单抗可逆地减少内源性RANKL。

著录项

来源
《Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA》 |2015年第10期|共7页
作者
Anastasilakis A. D.; Polyzos S. A.; Gkiomisi A.; Saridakis Z. G.; Digkas D.; Bisbinas I.; Sakellariou G. T.; Papatheodorou A.; Kokkoris P.; Makras P.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类骨科学（运动系疾病、矫形外科学）;
关键词
Bone mineral density; Bone turnover markers; Denosumab; RANKL; Sclerostin; Zoledronic acid;

机译：骨密度;骨转换标志物;Denosumab;RANKL;硬化蛋白;唑来膦酸;

相似文献

外文文献
中文文献
专利

1. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid [J] . Anastasilakis A. D., Polyzos S. A., Gkiomisi A., Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA . 2015,第10期

机译：曾接受唑来膦酸治疗的患者中地诺单抗与唑来膦酸的关系
2. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. [J] . David Henry, Saroj Vadhan-Raj, Vera Hirsh, Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer . 2014,第3期

机译：在晚期癌症患者中地诺美单抗与唑来膦酸的随机3期研究中延迟骨骼相关事件：对实体瘤患者数据的分析。
3. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. [J] . Rosen LS, Gordon D, Tchekmedyian S, Journal of Clinical Oncology . 2003,第16期

机译：唑来膦酸与安慰剂在肺癌和其他实体瘤患者的骨骼转移中的治疗：III期，双盲，随机试验-唑来膦酸肺癌和其他实体瘤研究组。
4. Effect of Nd:YAG laser light on post-extractive socket healing in rats treated with zoledronic acid and dexamethasone [C] . Giovanni Mergoni, Elisabetta Merigo, Pietro Passerini, Congress of the World Federation for Laser Dentistry . 2016

机译：ND：YAG激光对唑康酸和地塞米松治疗大鼠后萃取后颈疗的影响
5. Local, Intra-Articular Delivery of Zoledronic Acid as a Disease-Modifying Therapeutic for Post-Traumatic Osteoarthritis [D] . David, Michael Aaron 2019

机译：唑来膦酸的局部关节内递送作为创伤性骨关节炎的疾病改良疗法
6. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma [O] . TE Witzig, KM Laumann, MQ Lacy, -1

机译：冬季骨髓瘤患者单独的沙利度胺加唑醇与唑代酸的一期随机试验
7. Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study [O] . Scagliotti Giorgio Vittorio, Hirsh Vera, Siena Salvatore, 2012

机译：地诺单抗和唑来膦酸治疗的肺癌和骨转移患者的总体生存改善：一项来自随机3期研究的亚组分析

Denosumab versus zoledronic acid in patients previously treated with zoledronic acid

摘要

著录项

相似文献

相关主题

期刊订阅